Colgate-Palmolive Co. 10-Q Summary: Q2 2025
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2025. Colgate-Palmolive operates in two primary segments: Oral, Personal and Home Care and Pet Nutrition (Hill's Pet Nutrition). The company reported 808.2 million shares of common stock outstanding as of the period end. Approximately two-thirds of net sales are generated outside the U.S., with significant exposure to emerging markets.
Key Financial Metrics (Three Months Ended June 30, 2025)
- Net Sales: $5,110 million (up 1.0% vs. Q2 2024).
- Operating Profit: $1,080 million (down 1.1% vs. Q2 2024).
- Net Income (Attributable to Colgate): $743 million (up 1.6% vs. Q2 2024).
- Diluted EPS: $0.91 (up from $0.89 in Q2 2024).
- Gross Margin: 60.1% (down 50 bps vs. Q2 2024).
- Operating Margin: 21.1% (down 50 bps vs. Q2 2024).
- Cash Flow from Operations (6 months): $1,484 million (down 11% vs. prior year).
- Total Debt: $8,758 million (up from $7,949 million at year-end 2024).
- Cash and Equivalents: $1,215 million.
Material Changes vs. Prior Period
- Revenue Drivers: Net sales growth was driven by net selling price increases of 2.0%, partially offset by negative foreign exchange impacts of 1.0%. Volume was flat. Organic sales growth was 1.8%.
- Margin Pressure: Gross profit margin declined primarily due to significantly higher raw and packaging material costs (420 bps impact), partially offset by cost savings from "funding-the-growth" initiatives (250 bps) and higher pricing (80 bps).
- Acquisition Impact: The acquisition of Prime100 (Care TopCo Pty Ltd) in April 2025 contributed 0.2% to volume growth and added $214 million in goodwill to the Pet Nutrition segment.
- Restructuring: A new three-year "Productivity Program" was approved in July 2025, projected to incur $200–$300 million in pre-tax charges over three years. The prior 2022 Global Productivity Initiative concluded in 2024.
- Legal Settlements: The company reached a settlement in principle regarding the ERISA litigation matter in Q2 2025, resolving the matter for an amount equal to previously recorded charges ($65 million recorded in Q1 2025).
Guidance, Outlook, and Risks
- Outlook: Management expects global macroeconomic conditions to remain challenging due to inflation, high interest rates, and foreign currency volatility. Tariffs imposed by the U.S. (including on China) are expected to contribute to inflationary pressures, with estimated incremental gross costs of approximately $75 million in 2025.
- Capital Allocation: The company increased its quarterly dividend to $0.52 per share. A new $5 billion share repurchase program was authorized in March 2025; approximately $4.74 billion remained available as of June 30, 2025.
- Risks: Key risks include geopolitical tensions (Ukraine, Middle East), supply chain disruptions, raw material cost inflation, and ongoing legal proceedings (including Brazilian tax matters and talcum powder litigation).
- Tax Legislation: The "One Big Beautiful Bill Act" (OBBBA) was signed into law on July 4, 2025. Management is evaluating the impact but does not expect a material effect on consolidated financial statements.
Investor Verification Checklist
- Verify the impact of the new U.S. tariffs on raw material costs and the ability to pass these costs to consumers via pricing.
- Monitor the execution and cost realization of the new "Productivity Program" approved in July 2025.
- Review the status of the ERISA litigation settlement and confirm no further cash contributions are required beyond immaterial amounts.
- Assess the integration progress and performance contribution of the Prime100 acquisition in the Pet Nutrition segment.
- Track foreign exchange volatility, particularly in hyper-inflationary economies (Argentina, Nigeria, Turkey), which impacts reported sales and margins.
- Confirm the resolution timeline for the Brazilian tax assessments (approx. $108 million exposure) and talcum powder litigation.